Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View

Bayer (BAYRY) reported stronger-than-expected Q2 earnings of 35 cents per ADR, up 30.9% year-over-year due to lower interest and tax expenses, and sales of $12.18 billion, which also beat consensus. Performance was bolstered by significant growth in key Pharmaceuticals products like Nubeqa (+50.5%) and Kerendia (+67.1%), and a 2.2% increase in Crop Science sales, despite a 27.1% decline in Xarelto sales due to generic competition. Reflecting this improved operational strength, particularly in pharma, Bayer raised its 2025 sales guidance to €46-48 billion and its EBITDA outlook, signaling a more optimistic forecast amidst ongoing litigation challenges.

Analysis

Bayer AG delivered a strong second-quarter 2025 performance, beating consensus estimates on both revenue and earnings. Core earnings per ADR reached 35 cents, a 30.9% year-over-year increase, driven by lower interest and tax expenses, while sales of $12.18 billion surpassed expectations despite a 4.9% negative currency impact. The results underscore a successful strategic pivot within the Pharmaceuticals division, where robust sales growth from newer products like Nubeqa (+50.5%) and Kerendia (+67.1%) is effectively compensating for the steep 27.1% decline in Xarelto sales due to generic competition. The Crop Science division also demonstrated resilience with a 2.2% sales increase, primarily fueled by a 29.5% surge in Corn Seed & Traits, although this was tempered by weakness in Soybean and Insecticide sales due to regulatory issues. In contrast, the Consumer Health segment remained flat with just 0.2% growth, reflecting market challenges. Critically, the strong first-half execution prompted management to raise full-year 2025 guidance for both sales (to €46-€48 billion) and EBITDA (to €9.7-€10.2 billion), signaling confidence in the ongoing business momentum. While the pipeline shows promise with recent approvals for Eylea and Nubeqa, an FDA review extension for elinzanetant introduces a degree of regulatory uncertainty, and the persistent overhang from Roundup litigation remains a significant risk factor noted to impact the bottom line.

Key Decisions for Investors

• Investors should view the strong Q2 results and upgraded guidance as confirmation of the Pharmaceuticals division's successful portfolio transition, where the growth of Nubeqa and Kerendia is a key performance indicator to monitor against the managed decline of Xarelto.
• Given the stock's 63.1% year-to-date surge, it is prudent to assess whether the positive operational momentum is fully reflected in the current valuation before initiating or adding to positions.
• Closely monitor two key risk factors: any new developments or provisions related to the ongoing Roundup litigation and the outcome of the FDA's extended review for the new drug elinzanetant, as both could materially impact future sentiment and financial performance.